Treating Patients With Traumatic Chondral Lesions With Autologous Bone Marrow Cells Derived Engineered Tissues - Engineered Osteochondral Tissue

Exclusion Criteria

• •Disease Factor---
• •Previous cartilage repair surgery (OATS or ACI/MACI) in the index knee
• •Previous injectional treatments such as HA/PRP/stem cell in the index knee within 3 months before informed consent
• •Presence of a clinically relevant patellofemoral cartilage lesion in the index knee (patella/trochlea/both)
• •Inflammatory joint disease (specific or non-specific arthritis)
• •Metabolic diseases (gout or rheumatism)
• •Advanced Osteoarthritis (Radiologically apparent degenerative joint disease in the target knee as determined by Kellgren \& Lawrence Grade \>2)
• •Osteochondritis dissecans
• •Multiple or uncontained lesions as detected by MRI or arthroscopy
• •Uncorrected ligament deficiency
• •Uncorrected varus or valgus malalignment exceeding 5°
• •Ongoing Infection or skin diseases at target knee joint
• •Significant meniscal loss
• •Patient Factor---
• •Subjects who are not able or not willing to give voluntary, written informed consent to participate in this study
• •Skeletal immaturity
• •Female subjects who are pregnant or lactating
• •Body mass index \> 30 kg/m2
• •Malignancy
• •Steroid therapy by systemic or intra-articular route within the last 60 days before informed consent or intramuscular or oral steroids within the last 30 days before informed consent
• •Contraindications to MR imaging
• •Drug addiction (including narcotic, anesthetic or alcohol addiction)
• •Patients who are at higher risk for post-surgical bleeding (e.g., bleeding disorder; taking anticoagulants except low dose aspirin
• •Patients who are at higher risk for post-surgical infection (e.g., taking immunosuppressants; have a severe infection or a history of serious infection)
• •Known allergy to porcine/bovine collagen
• •Any concomitant painful or disabling disease of the spine, hips, or lower limbs that would interfere with evaluation of the afflicted knee
• •Patients with human immunodeficiency virus, hepatitis, or syphilis
• •Any clinically significant or symptomatic vascular or neurologic disorder of the lower extremities
• •Poor general health condition as judged by investigator
• •Unable to do follow up